Izotropic to Present at Investor Conference February 6th
Izotropic (OTCQB: IZOZF) has announced its upcoming presentation at the Small Cap Growth Virtual Investor Conference on February 6, 2025. CEO Robert Thast will present from 3:00-3:30 PM EST, discussing the company's recent achievements, regulatory approvals in the U.S. and EU, near-term objectives, and funding options.
This marks the company's first public presentation since revealing its new regulatory strategy for U.S. FDA approval and timeline for launching IzoView, their dedicated breast CT imaging system. The device features contrast-enhancement for breast cancer screening, working alongside 3D mammography for patients with dense breast tissue.
The virtual conference will include a live Q&A session, and attendance is complimentary for individual and institutional investors, advisors, and analysts. Those unable to attend can access an archived webcast of the presentation.
Izotropic (OTCQB: IZOZF) ha annunciato la sua prossima presentazione alla Small Cap Growth Virtual Investor Conference il 6 febbraio 2025. Il CEO Robert Thast presenterà dalle 15:00 alle 15:30 EST, discutendo dei recenti successi dell'azienda, delle approvazioni normative negli Stati Uniti e nell'UE, degli obiettivi a breve termine e delle opzioni di finanziamento.
Questa sarà la prima presentazione pubblica dell'azienda dalla rivelazione della sua nuova strategia normativa per l'approvazione della FDA statunitense e del calendario per il lancio di IzoView, il loro sistema di imaging dedicato alla tomografia computerizzata per il seno. Il dispositivo presenta un miglioramento del contrasto per lo screening del cancro al seno, funzionando in sinergia con la mammografia 3D per pazienti con tessuto mammario denso.
La conferenza virtuale includerà una sessione di domande e risposte dal vivo, e la partecipazione è gratuita per investitori individuali e istituzionali, consulenti e analisti. Coloro che non possono partecipare possono accedere a una registrazione del webcast della presentazione.
Izotropic (OTCQB: IZOZF) ha anunciado su próxima presentación en la Small Cap Growth Virtual Investor Conference el 6 de febrero de 2025. El CEO Robert Thast presentará de 3:00 a 3:30 PM EST, hablando sobre los logros recientes de la empresa, las aprobaciones regulatorias en EE. UU. y la UE, los objetivos a corto plazo y las opciones de financiamiento.
Este será el primer evento público de la empresa desde que reveló su nueva estrategia regulatoria para la aprobación de la FDA de EE. UU. y el cronograma para el lanzamiento de IzoView, su sistema de imágenes de tomografía computarizada dedicado a senos. El dispositivo presenta un realce de contraste para el cribado de cáncer de mama, funcionando junto a la mamografía en 3D para pacientes con tejido mamario denso.
La conferencia virtual incluirá una sesión de preguntas y respuestas en vivo, y la asistencia es gratuita para inversores individuales e institucionales, asesores y analistas. Aquellos que no puedan asistir pueden acceder a una grabación del webcast de la presentación.
아이소트로픽 (OTCQB: IZOZF)는 2025년 2월 6일에 열리는 Small Cap Growth Virtual Investor Conference에서 발표할 예정이라고 발표했다. CEO 로버트 타스트는 동부 표준시 기준 오후 3시부터 3시 30분까지 발표하며, 회사의 최근 성과, 미국 및 EU의 규제 승인, 단기 목표 및 자금 옵션에 대해 논의할 예정이다.
이번 발표는 회사가 미국 FDA 승인을 위한 새로운 규제 전략과 IzoView 런칭 일정이 공개된 이후 첫 번째 공개 발표이다. 이 장치는 유방암 선별을 위한 대비 강화 기능을 갖추고 있으며, 조밀한 유방 조직을 가진 환자를 위해 3D 유방 촬영과 함께 작동한다.
가상 회의에서는 라이브 Q&A 세션이 포함되며, 개인 및 기관 투자자, 자문 및 분석가에게 무료로 참여할 수 있다. 참석할 수 없는 사람들은 발표의 아카이브 웹캐스트를 이용할 수 있다.
Izotropic (OTCQB: IZOZF) a annoncé sa prochaine présentation lors de la Small Cap Growth Virtual Investor Conference le 6 février 2025. Le PDG Robert Thast présentera de 15h00 à 15h30 EST, abordant les réalisations récentes de l'entreprise, les approbations réglementaires aux États-Unis et dans l'UE, les objectifs à court terme et les options de financement.
Cette présentation constitue la première présentation publique de l'entreprise depuis la révélation de sa nouvelle stratégie réglementaire pour l'approbation de la FDA américaine et le calendrier de lancement de IzoView, leur système d'imagerie dédié à la tomodensitométrie pour le sein. Le dispositif propose un rehaussement de contraste pour le dépistage du cancer du sein, fonctionnant avec la mammographie 3D pour les patientes ayant un tissu mammaire dense.
La conférence virtuelle comprendra une session de questions-réponses en direct, et la participation est gratuite pour les investisseurs individuels et institutionnels, les conseillers et les analystes. Ceux qui ne peuvent pas assister auront accès à une webdiffusion archivée de la présentation.
Izotropic (OTCQB: IZOZF) hat seine bevorstehende Präsentation auf der Small Cap Growth Virtual Investor Conference am 6. Februar 2025 bekannt gegeben. CEO Robert Thast wird von 15:00 bis 15:30 Uhr EST präsentieren und über die jüngsten Erfolge des Unternehmens, regulatorische Genehmigungen in den USA und der EU, kurzfristige Ziele und Finanzierungsmöglichkeiten sprechen.
Dies ist die erste öffentliche Präsentation des Unternehmens seit der Bekanntgabe seiner neuen Regulierungsstrategie für die FDA-Zulassung in den USA und dem Zeitrahmen für den Start von IzoView, ihrem speziellen CT-Bildgebungssystem für die Brust. Das Gerät bietet eine Kontrastverbesserung für das Screening von Brustkrebs und arbeitet zusammen mit der 3D-Mammographie für Patientinnen mit dichtem Brustgewebe.
Die virtuelle Konferenz umfasst eine Live-Q&A-Session und die Teilnahme ist kostenlos für Einzel- und institutionelle Investoren, Berater und Analysten. Personen, die nicht teilnehmen können, haben Zugriff auf ein archiviertes Webcast der Präsentation.
- None.
- None.
- CEO to present overview of Company value proposition, unique catalysts, and near-term objectives -
- Event includes live Q and A, attendance is complimentary -
- Individual and institutional investors, advisors, and analysts welcome -
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 3, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that CEO Robert Thast will be presenting at the Small Cap Growth Virtual Investor Conference this week and will be covering key aspects of the Company's recent achievements, U.S. and EU regulatory approvals, near-term-objectives, and funding options.
Date: February 6, 2025
Time: 3:00 - 3:30 pm EST / 12:00 - 12:30 pm PST
1 x 1 Meetings: See availability here: https://calendly.com/izotropic/meeting-with-ceo
This will be the first public presentation by Izotropic since unveiling its new regulatory strategy for U.S. FDA approval and timelines to market launch of its first medical imaging device, IzoView- a dedicated breast CT imaging system, with contrast-enhancement for breast cancer screening adjunctive to digital breast tomosynthesis, commonly referred to as 3D mammography, for patients with dense breast tissue.
After the formal presentation, attendees will have the opportunity and are encouraged to ask relevant questions through an interactive portal. For anyone registered who cannot attend the live event, an archived webcast will be made available.
Please pre-register at the following link:
https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/4849543/izotropic-corporation-otcqb-izozf-cse-izo
About Izotropic:
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Izotropic Corporation
Robert Thast
Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-800-IZOCORP ext. 3
Email: bthast@izocorp.com
General Inquiries
Telephone: 1-604-825-4778 or 1-800-IZOCORP ext. 1
Email: info@izocorp.com
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239311
FAQ
When is Izotropic (IZOZF) presenting at the Small Cap Growth Virtual Investor Conference?
What will be covered in Izotropic's (IZOZF) February 2025 investor presentation?
What is Izotropic's (IZOZF) IzoView system designed for?
How can investors attend Izotropic's (IZOZF) February 2025 presentation?
Will there be a Q&A session during Izotropic's (IZOZF) February 2025 presentation?
